That’s right—Contagion® will
return to ID Week this year—in San Diego, California—to provide exclusive written and video coverage on the biggest conference dedicated specifically to infectious diseases.
Each year, ID Week
serves as a forum for health care professionals of all different backgrounds and institutions to work together and learn from each other’s research, insights, and expertise on several important infectious disease topics.
spoke with several key opinion leaders in the realm of infectious disease on a plethora of disease topics, including high readmission rates among patients with skin and soft tissue infections
, the importance of new hepatitis C treatments
, and the prevalence of Powassan virus
This year’s plenary sessions include several notable speakers. The opening plenary—Evolution and Revolution: Infectious Disease Promise and Challenges in the 21st Century—will include Anthony Fauci, MD, FIDSA, who will discuss the challenges of pandemic preparedness, and Margaret Hamburg, MD, who will shed light on a new strategy that may help prevent future epidemics. The closing plenary—21st Century Cures in Infectious Disease—will include James E. Crowe Jr., MD, FIDSA, will be joined with Christopher Karp, MD, FIDSA, and David Thomas, MD, MPH, FIDSA. Topics discussed will include the use of monoclonal antibodies to treat or protect against infectious diseases and the role of treatment when it comes to eliminating HCV infection and what obstacles still stand in the way of eliminating HCV as a whole in the United States.
At this year’s conference, we have identified several “hot button” sessions that we will provide coverage on in the upcoming weeks. One big topic that hits close to home in San Diego, is hepatitis A. Monique Foster, MD, MPH, speaking on the “surprising return of hepatitis A” among homeless and IDU populations. Over the past few months, Contagion
has been reporting on the ongoing outbreak
that has sprung up in San Diego, which has infected
461 individuals and claimed 17 lives thus far. Dr. Foster will be joined by Eric D. McDonald, MD, MPH to shed light on the issue.
Other important topics include: exploring the epidemiology, challenges, and management of Candida auris
, an emerging fungal threat
; looking at key elements that should be incorporated into CAUTI
, and CDI
prevention programs; practice-changing new clinical trials pertaining to non-HIV antivirals
, antibacterials, and antifungals
, and more.
In addition, Contagion®
will be interviewing several presenters to discuss several new antibiotics in the pipeline. Some of these antibiotics include, but are not limited to:
- Imipenem-Relebactam: Relebactam is an investigational, intravenous, class A and C, beta-lactamase inhibitor being evaluated in combination with imipenem/cilastatin to treat complicated Gram-negative bacterial infections.
- Omadacycline: A novel first-in-class aminomethylcycline that is active against skin and pneumonia pathogens, including community-acquired methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, Haemophilus influenza, and Legionella.
- Eravacycline: A novel, fully-synthetic fluorocycline antibiotic being used to treat several serious infections, including those caused by multidrug-resistant pathogens such as carbapenem-resistant enterobacteriaceae (CRE), Acinetobacter baumannii, and colistin-resistant bacteria carrying the mcr-1 gene; it is currently in development for the treatment of complicated intra-abdominal infections and complicated urinary tract infections.
If there are any specific presentations from the “Program
” that you would like us to cover, please share your thoughts on our Twitter or Facebook pages and we will do our best to accommodate your requests.
Going to ID Week? Be sure to swing by our booth (#449) to say hello and grab a publication.
Not going to ID Week? Be sure to sign up for our Conference update. Just click: here
Also, be sure to follow us on Twitter
and like us on Facebook
for additional coverage.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.